Tuesday, 28 August 2012
M. C. Ostojic, Helen M. Colhoun(Edinburgh Cancer Research), E. Kawada-Watanabe, C. C. Wun, K. Nakanishi, K. Aznaouridis, G. Chlapoutakis, P. Deedwania, Kunio Matsumoto(Kanazawa University), A. Breazna, Thomas Garm Pedersen, L. Lioni, Nobutoshi Hagiwara, Vladan Vukčević(University of Belgrade), V. Stojanov, Junji Yamaguchi, Shinsaku Fukuda, Akihiko Takagi, Biljana Parapid(University of Belgrade), I. Tatsis, G. A. Hitman, Takahiro Muro, S. Ehara, Ryota Koyanagi, H. Inanami, D. A. Demicco, Nikolaos Ioakeimidis, V. Tzamou, N. M. Milic, Andrew Neil(University of Oxford), Costas Tsioufis, B. Beleslin(University of Belgrade), O. M. S. Nedeljkovic-Arsenovic, Biljana Obrenović-Kirćanski
Cited by 2
Related Papers
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k